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A modeling approach termed ‘nicotine bridging’ is presented to estimate exposure to mainstream smoke
constituents. The method is based on: (1) determination of harmful and potentially harmful constituents
(HPHC) and in vitro toxicity parameter-to-nicotine regressions obtained using multiple machine-smoking
protocols, (2) nicotine uptake distributions determined from 24-h excretion of nicotine metabolites in a
clinical study, and (3) modeled HPHC uptake distributions using steps 1 and 2. An example of ‘nicotine
bridging’ is provided, using a subset of the data reported in Part 2 of this supplement (Zenzen et al.,
2012) for two conventional lit-end cigarettes (CC) and the Electrically Heated Cigarette Smoking System
(EHCSS) series-K6 cigarette. The bridging method provides justiﬁed extrapolations of HPHC exposure dis-
tributions that cannot be obtained for smoke constituents due to the lack of speciﬁc biomarkers of expo-
sure to cigarette smoke constituents in clinical evaluations. Using this modeling approach, exposure
reduction is evident when the HPHC exposure distribution curves between the MRTP and the CC users
are substantially separated with little or no overlap between the distribution curves.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction changes in physical and chemical composition of the smoke overMainstream (MS) cigarette smoke constituent yields are nor-
mally quantiﬁed and reported using a smoking regimen developed
by the Federal Trade Commission (FTC) (Federal Register, 1967),
and adopted by the International Organization for Standardization
(ISO) (International Organization for Standardization, 2000a,b,c),
with minor changes. These two protocols are intended solely to
provide comparative information about the level of smoke constit-
uents in different brands of cigarettes by pufﬁng cigarettes accord-
ing to a convention of analytical standards, but cannot be used to
predict smoke constituent uptake by the ‘‘average’’ smoker (Gori
and Lynch, 1985; Baker, 2002; Borgerding and Klus, 2005; Federal
Trade Commission, 2008a).
MS cigarette smoke consists of an aerosol containing liquid
droplets (particulate phase) suspended in the gas–vapor phase,
and is generated by overlapping burning, pyrolysis, pyrosynthesis,
distillation, sublimation, and condensation processes, withchorp).
-NC-ND license.time (Baker, 1999; Borgerding and Klus, 2005). Nicotine is mainly
present (>99%) in the particulate phase of the MS smoke aerosol
(Seeman et al., 2004), and the nicotine dose obtained from a
cigarette is subject to substantial inter- and intra-individual differ-
ences in smoking behavior (Scherer et al., 2007; Lindner et al.,
2011). Smoking a cigarette can be described by distinct physical
processes: Pufﬁng, mouth hold, inhalation, and exhalation
(Bernstein, 2004). Little buccal absorption of nicotine occurs from
acidic smoke of ﬂue-cured tobacco (pH 5.5–6.0), even when held
in the mouth (Gori et al., 1986), whereas nicotine from more alka-
line air-cured tobacco smoke (pH > 6.5) is efﬁciently absorbed
across the buccal mucosa (Armitage et al., 1978). Regardless of
the pH of cigarette smoke, extensive retention (90–100%) of
nicotine occurs when the smoke taken into the mouth is inhaled
(Robinson and Yu, 2001; Armitage et al., 2004a,b; Feng et al.,
2007). Numerous experimental studies have quantiﬁed the pul-
monary retention of a range of additional HPHC present in both
the gas–vapor and particulate phase of MS cigarette smoke which
is similar or lower than that of nicotine (Dalhamn et al., 1968; Gori
et al., 1986; Armitage et al., 2004a,b; Baker and Dixon, 2006; Feng
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2007, 2008a,b,c).
Retained nicotine is extensively metabolized to a number of dif-
ferent metabolites that can be quantiﬁed in biological ﬂuids of
smokers (Hukkanen et al., 2005; Tricker, 2006). However, because
no single smoking machine regimen will adequately reﬂect human
smoking behavior (Institute of Medicine 2001; Baker, 2002; Bor-
gerding and Klus, 2005; World Health Organization Study Group
on Tobacco Product Regulation, 2007, 2008), only poor correlations
exist between smoke nicotine yields determined using machine-
smoking protocols and nicotine-derived biomarker of exposure
estimates in smokers (Russell et al., 1980; Rickert and Robinson,
1981; Benowitz and Jacob, 1984; Gori and Lynch, 1985; Diding,
1987; Andersson et al., 1997; Byrd et al., 1998; Jarvis et al., 2001;
Ueda et al., 2002; Scherer et al., 2007; Mendes et al., 2009; Lindner
et al., 2011). Consequently, the U.S. Federal Trade Commission
(FTC) has ofﬁcially rescinded its guidance for reported smoking
machine tar and nicotine yields (Federal Trade Commission,
2008b), while increased interest has occurred within the tobacco
control community to develop alternative protocols which better
reﬂect smoker exposure to harmful and potentially harmful con-
stituents (HPHC) (World Health Organization Study Group on To-
bacco Product Regulation, 2004, 2007; Hammond et al., 2006,
2007; Marian et al., 2009).
In this study, a ‘nicotine bridging’ method is described which
uses experimentally measured human smoking topography
parameters (i.e., puff volume, puff frequency, and puff duration)
and 24-h urinary excretion of nicotine metabolites as a measure
of nicotine uptake to develop multiple machine smoking protocols
to provide smoke nicotine yields that more closely correspond to
experimentally determined nicotine uptake estimates in smokers
(Urban et al., 2008). This concept is used to evaluate HPHC-to-nic-
otine and in vitro toxicity-to-nicotine relationships for 2 conven-
tional cigarettes (Marlboro, Philip Morris One) (M6UK, PM1) and
the EHCSS-K6 smoked according to ISO and 15 different ma-
chine-smoking regimens to reﬂect ‘human pufﬁng behavior’
(Schorp et al., 2012; Zenzen et al., 2012). Human smoking behavior
was determined using nicotine uptake distributions derived from
nicotine metabolite excretion data obtained in two clinical studies
(Tricker et al., 2012; Lindner et al., 2011). The two approaches are
then combined (‘nicotine bridging’) to model HPHC uptake propor-
tional to nicotine uptake distributions as a means of assessment of
exposure to HPHC for which biomarkers of exposure are not avail-
able (Urban and Schorp, 2006).2. Materials and methods
2.1. Smoking protocols and test and comparator cigarettes
Study cigarettes were analyzed for tar and nicotine according to
ISO methods. All study cigarettes were conditioned according to
ISO standard 3402 (International Organization for Standardization,
1991). Conventional cigarettes were smoked on smoking machines
according to ISO standard 3308 (International Organization for
Standardization, 2000a). Tar, nicotine and carbon monoxide (CO)
were determined according to IS0 standards 4387, 10315, and
8454, respectively (International Organization for Standardization,
2000b,c, 1995). Mainstream smoke from EHCSS cigarettes was gen-
erated on a modiﬁed smoking machine with a carousel adapted to
use the EHCSS series K lighter. The EHCSS smoke generation con-
formed to ISO standard 3308, and some slight technical deviations
were required. The ISO yields as declared on the cigarette packag-
ing were as follows: Marlboro (M6UK; 6 mg tar, 0.5 mg nicotine,
and 7.0 mg CO), Philip Morris One (PM1; 1 mg tar, 0.1 mg nicotine,
and 2.0 mg CO), and EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and0.6 mg CO). Mainstream smoke was also analyzed for 44 additional
HPHC according to ISO conditions plus 15 experimental smoking
regimens reﬂecting ‘human pufﬁng behavior’ (Zenzen et al.,
2012). The data used represent a subset of the data set reported
by Zenzen et al. (2012) to illustrate the principle of the ‘nicotine
bridging’ method.
2.2. HPHC yields and in vitro toxicological parameters
Five ‘‘toxicological parameters’’ were determined for main-
stream smoke total particulate matter (TPM) using the Salmonella
typhimurium reverse mutation assay with tester strains TA98,
TA100, and TA1537 with S9 metabolic activation (Organization
for Economic Co-operation and Development, 1997), and the neu-
tral red uptake (NRU) assay for both mainstream smoke gas-vapor
phase (GVP) and TPM (Borenfreund and Puerner, 1985).
2.3. Biomarker measurements in urine
Urinary excretion of biomarkers of exposure to nicotine and se-
lected cigarette smoke HPHC (1,3-butadiene, 4-(methylnitrosami-
no)-1-(3-pyridyl)-1-butanone [NNK], acrolein, benzene, CO,
pyrene, and o-toluidine) were determined in a clinical study com-
paring exposure of smokers (N = 32 smokers per group) of the
M6UK, PM1, and EHCSS-K6 cigarettes (Tricker et al., 2012). Bio-
markers of exposure were determined in 24 h urine samples col-
lected on study days 3–8 after randomization to the test
cigarettes. Nicotine uptake was expressed as excretion of nicotine
equivalents in 24 h urine (Neq; the calculatedmolar sumof the con-
centrations of nicotine, cotinine, trans-30-hydroxycotinine, and their
respective glucuronide conjugates). Nicotine uptake, expressed as
24 h urine excretion of Neq, was also determined in a European
population of smokers from the UK, Germany, and Switzerland
(Lindner et al., 2011). Smokerswere randomized according to differ-
ent cigarette ISO tar categories (TC): TC1 (1–4 mg ISO tar; N = 409),
TC2 (5–7 mg ISO tar, N = 399), and TC3 (8–12 mg ISO tar, N = 387).
2.4. ‘Nicotine bridging’ method
The nicotine bridging method uses a three-step approach as
shown in Fig. 1. This approach is based on: (1) MS smoke HPHC
or in vitro toxicity parameter-to-nicotine regressions obtained
using multiple machine smoking protocols, (2) nicotine uptake dis-
tributions from clinical studies, and (3) modeled HPHC uptake dis-
tributions (Urban and Schorp, 2006). For a 5 days average estimate
of nicotine uptake, determined as Neq excretion per day for each
smoker, the corresponding smoke constituent uptake was esti-
mated based on the corresponding regression equation (i.e., using
the slope and the intercept of the HPHC-to-nicotine yield). In this
way, a modeled HPHC uptake value for each smoker was obtained
which can be displayed as a frequency distribution for all smokers.
This method is based on the underlying assumptions that (i) pro-
portionality exists between the yield of different HPHC to nicotine
(Zenzen et al., 2012), and (ii) that uptake of each HPHC is propor-
tional to the nicotine uptake distribution. The latter is a rather con-
servative assumption as almost complete uptake of nicotine occurs
when cigarette smoke reaches the small airways of the lung, while
the retention of other HPHC may be lower (Robinson and Yu, 2001;
Armitage et al., 2004a,b; Feng et al., 2007).
For each HPHC/in vitro toxicity parameter the intercept (a) and
the slope (b) of the corresponding regression equation was deter-
mined using standard linear regression analysis. The coefﬁcient
of determination r2 was used to assess the quality of the linear
relationship. Examples of graphical representations of HPHC-to-
nicotine relationships and further interpretation are reported by
Zenzen et al. (2012).
Fig. 1. The concept of ‘Nicotine Bridging’.
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ware V. 9.1.3 and later V.9.2 (SAS Institute, Cary, NC). Linear regres-
sions were used for untransformed data and transformed data
(natural logarithms). Excretion of Neq was modeled using a normal
distribution for CC (PM1 and M6UK) and a lognormal distribution
for the EHCSS-K6 cigarette. The choice of using either a normal or a
lognormal distribution was based on the measure of ‘skewness’
and the Kolmogorov–Smirnov test. Curve ﬁtting was performed
using SAS routine PROC UNIVARIATE.
The concept of ‘Percentage Change’ was used as an index for
comparison of two overlapping distributions in which the CC was
set as the reference (Fig. 2). The mean, which is identical to the
mode for both normal and lognormal distributions was used to
characterize the difference of two distributions for a HPHC from
two different cigarettes. Thus, the percentage change of the mode
of the EHCSS-K6 cigarette to the mean of a CC was used to provide
a graphical display in which changes between the EHCSS-K6 andFig. 2. Theoretical overlay plot of exposure frequency distributions of a smoke constit
Overlap.CC were displayed as a negative value if the exposure was reduced
while smoking EHCSS-K6, and as a positive value when exposure
was increased while smoking EHCSS-K6.
A second index, the ‘Extent of Overlap’, was used to compare
two overlapping distributions, as depicted in Fig. 2. The overlap
area under a normal distribution was calculated using the Z-func-
tion in which the mean and standard deviation in the Z-function
are properties of the normal distribution, and ‘‘L’’ was deﬁned as
the value of the x-axis of the normal distributions where the fre-
quencies of both normal distributions are equal. The percentage
distribution area of overlap was computed using the CDF-FUNC-
TION of the SAS program.
3. Results
Of the HPHC determined in MS cigarette smoke, 15 of 49
HPHC were constituents were below the limit of quantiﬁcationuent from two different cigarettes. Panel (a) Percent Change; Panel (b) Extent of
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of quantiﬁcation in the CC (Zenzen et al., 2012). Therefore,
regression analysis was restricted to the remaining 34 smoke con-
stituents. Linear relationships were observed for HPHC-to-nico-
tine and toxicity parameter-to-nicotine yields of the M6UK and
PM1 cigarettes. Nineteen of 33 smoke HPHC-to-nicotine yields
were linear, while the remaining smoke constituents and all
in vitro toxicity parameter-to-nicotine yields were best described
by non-linear (exponential) relationships in the EHCSS-K6Table 1
Smoke constituent yield/toxicity parameter (n = 38) to mean nicotine yield regressions.
Cigarette smoke constituent/toxicity parameter M6UK
r2 Intercept Slope
TPM 0.98 4.04 20.63
Tar 0.99 1.66 14.57
Water 0.90 2.38 5.06
Carbon monoxide 0.99 0.89 16.68
Aliphatic dienes
1,3-Butadiene 0.86 1.22 41.99
Isoprene 0.93 72.24 553.2
Aldehydes
Formaldehyde 0.94 14.68 51.40
Acetaldehyde 0.94 108.7 821.2
Acrolein 0.92 11.86 92.02
Propionaldehyde 0.93 6.05 66.25
Acid derivates
Acetamide 0.98 3.29 12.32
Acrylonitrile 0.99 12.16 37.61
Nitro compounds
2-Nitropropane 0.94 0.79 11.86
Aromatic amines
o-Toluidine 0.98 4.36 63.71
o-Anisidine 0.95 0.35 2.36
2-Naphthylamine 0.84 2.56 5.12
4-Aminobiphenyl 0.96 0.03 1.61
Inorganic compounds
Nitrogen oxides 0.97 20.73 146.6
Ammonia 0.94 1.87 14.75
Hydrogen cyanide 0.73 60.99 166.8
Monocyclic aromatic hydrocarbons
Benzene 0.97 1.16 47.93
Toluene 0.94 11.48 92.66
Styrene 0.98 7.08 15.87
N-nitrosamines
NNN 0.75 25.19 48.95
NNK 0.76 17.35 34.25
Phenols
Phenol 0.73 0.19 15.35
Catechol 0.96 11.72 47.96
Polycyclic aromatic hydrocarbons
Benz[a]anthracene 0.95 0.71 14.90
Benzo[b]ﬂuoranthene 0.96 0.51 7.44
Benzo[j]ﬂuoranthene 0.94 0.05 4.76
Benzo[a]pyrene 0.95 1.02 8.76
Indeno(1,2,3-cd)pyrene 0.94 0.22 4.28
Pyrene 0.94 2.93 51.73
Cytotoxicity
1/EC50: GVP fraction 0.95 45.38 158.7
1/EC50: TPM fraction 0.97 6.04 167.2
Bacterial mutagenicity (TPM fraction)
Strain TA98 with S9 0.98 4887 23520
Strain TA100 with S9 0.93 4264 11786
Strain TA1537 with S9 0.90 48.20 5349
Abbreviations: GVP, gas–vapor phase; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta
linear (NL).
a Linear regression model either on untransformed or log-transformed data. A linear m
cigarettes. Linear and non-linear models (Ln(y) = a + bnicotine) were used for the EHCScigarette. This suggests that these HPHC reﬂect a change in aero-
sol composition as a function of pufﬁng intensity. The intercept,
slope, and coefﬁcient of determination (r2) of all regressions are
presented in Table 1.
Table 2 presents two-sided 95% conﬁdence intervals for the
estimated HPHC concentrations and toxicological effects at a nico-
tine concentration of 1.08 mg/cigarette for all regressions. The nic-
otine concentration of 1.08 mg/cigarette was chosen because it
represents the 90th percentile of the nicotine uptake distributionPM1 EHCSS-K6
r2 Intercept Slope r2 Intercept Slope Regressiona
0.99 0.61 13.96 0.83 3.64 18.83 L
0.99 0.51 11.60 0.74 1.79 0.08 L
0.87 0.11 1.36 0.79 1.84 7.75 L
0.87 1.21 11.83 0.83 0.23 2.34 NL
0.94 2.11 37.39 0.65 1.12 1.95 NL
0.97 6.21 591.7 0.52 10.84 88.18 L
0.93 0.80 16.52 0.77 9.62 40.65 L
0.95 63.53 816.4 0.83 90.28 268.6 L
0.94 5.64 74.31 0.85 11.70 50.85 L
0.94 4.79 67.37 0.78 3.10 13.89 L
0.97 0.91 7.08 0.97 0.39 5.71 L
0.99 2.62 33.69 0.79 0.36 2.25 NL
0.90 1.55 15.64 0.94 1.65 12.54 L
0.97 2.08 72.05 0.96 0.26 3.75 NL
0.96 0.04 3.03 0.92 0.08 0.69 L
0.92 0.73 7.54 0.91 0.03 3.38 NL
0.94 0.13 1.50 0.88 0.08 0.36 L
0.83 58.04 99.34 0.80 10.86 77.89 L
0.20 5.78 3.83 0.85 6.41 26.87 L
0.92 21.15 129.6 0.71 4.16 33.31 L
0.94 0.05 53.11 0.77 0.20 2.58 NL
0.97 5.16 103.0 0.75 0.84 1.96 NL
0.96 2.08 13.32 0.79 0.12 2.17 NL
0.69 33.33 32.38 0.98 0.02 73.78 L
0.92 10.20 41.98 0.99 0.89 22.63 L
0.99 2.28 20.84 0.95 0.05 4.71 NL
0.99 1.88 58.06 0.93 3.24 28.48 L
0.98 0.21 15.03 0.91 0.010 4.67 NL
0.98 0.14 8.19 0.92 0.010 3.82 NL
0.99 0.50 4.17 0.95 0.003 4.83 NL
0.98 0.13 9.38 0.88 0.010 3.97 NL
0.98 0.04 4.29 0.89 0.009 3.44 NL
0.99 0.78 52.90 0.84 0.088 3.73 NL
0.92 17.66 123.0 0.84 15.80 1.51 NL
0.99 9.22 161.4 0.97 7.69 2.29 NL
0.99 509.3 29591 0.91 146.9 3.54 NL
0.96 637.3 16138 0.72 103.5 3.12 NL
0.97 48.84 4895 0.84 32.79 3.32 NL
none; NNN, N-nitrosonornicotine; TPM, total particulate matter; Linear (L); Non-
odel (y = a + bnicotine) was used with un-transformed data for the M6UK and PM1
S-K6 cigarette.
Table 2
Comparison of 95% conﬁdence intervals of smoke constituent concentrations/toxicological parameter (n = 39) at a nicotine concentration of 1.08 mg/cig. (equivalent to the
90th%ile of nicotine uptake distribution for EHCSS-K6).
Cigarette
smoke constituent/toxicity parameter
Unit M6UK PM1 EHCSS-K6 EHCSS-K6 vs.
Lower
95% CL
Upper
95% CL
Lower
95% CL
Upper
95% CL
Lower
95% CL
Upper
95% CL
M6UK PM1
TPM (mg/cig.) 15.80 20.68 13.61 15.32 19.29 28.65 = ⁄ H
Tar (mg/cig.) 13.02 15.14 11.35 12.70 9.39 15.97 = =
Nicotine (mg/cig.) 1.02 1.14 1.04 1.12 0.96 1.20 = =
Water (mg/cig.) 1.64 4.52 0.96 1.76 8.05 12.37 ⁄ H ⁄ H
Carbon monoxide (mg/cig.) 15.83 18.43 10.52 17.45 1.52 5.26 ⁄ L ⁄ L
Aliphatic dienes
1,3-Butadiene (lg/cig.) 29.69 58.57 35.56 49.42 3.94 21.12 ⁄ L ⁄ L
Isoprene (lg/cig.) 392.7 657.7 549.8 716.0 56.78 155.40 ⁄ L ⁄ L
Aldehydes
Formaldehyde (lg/cig.) 30.84 50.83 13.71 20.36 41.00 66.04 = ⁄ H
Acetaldehyde (lg/cig.) 614.6 941.6 689.5 47.0 312.1 448.7 ⁄ L ⁄ L
Acrolein (lg/cig.) 66.65 108.4 61.29 87.93 54.60 78.62 = =
Propionaldehyde (lg/cig.) 51.02 79.98 55.93 80.01 14.01 22.19 ⁄ L ⁄ L
Acid derivates
Acetamide (lg/cig.) 8.67 11.37 5.76 7.73 5.16 6.40 ⁄ L =
Acrylonitrile (lg/cig.) 25.47 31.45 30.66 36.87 2.12 8.08 ⁄ L ⁄ L
Nitro compounds
2-Nitropropane (ng/cig.) 9.59 14.44 11.89 18.79 13.40 16.98 = =
Aromatic amines
o-Toluidine (ng/cig.) 64.95 81.39 67.23 84.22 9.58 23.57 ⁄ L ⁄ L
o-Anisidine (ng/cig.) 2.44 3.35 2.85 3.77 0.56 0.76 ⁄ L ⁄ L
2-Naphthylamine (ng/cig.) 6.30 9.87 7.26 10.48 0.79 2.27 ⁄ L ⁄ L
4-Aminobiphenyl (ng/cig.) 1.50 2.05 1.47 2.01 0.25 0.38 ⁄ L ⁄ L
Inorganic compounds
Nitrogen oxides (lg/cig.) 155.8 202.3 130.9 199.8 72.57 117.40 ⁄ L ⁄ L
Ammonia (lg/cig.) 11.44 16.68 5.40 14.42 29.36 41.51 ⁄ H ⁄ H
Hydrogen cyanide (lg/cig.) 34.28 204.0 89.07 148.6 19.51 44.11 = ⁄ L
Monocyclic aromatic hydrocarbons
Benzene (lg/cig.) 45.40 60.45 47.14 67.48 1.40 7.24 ⁄ L ⁄ L
Toluene (lg/cig.) 69.01 108.2 92.43 119.6 3.63 13.46 ⁄ L ⁄ L
Styrene (lg/cig.) 8.01 12.10 10.09 14.51 0.64 2.34 ⁄ L ⁄ L
N-nitrosamines
NNN (lg/cig.) 54.09 102.0 51.54 85.06 73.27 86.12 = =
NNK (lg/cig.) 37.95 70.74 45.80 65.27 22.11 24.99 ⁄ L ⁄ L
Phenols
Phenol (lg/cig.) 8.40 24.37 18.30 22.17 4.53 15.49 ⁄ L ⁄ L
Catechol (lg/cig.) 55.15 71.89 60.69 68.48 23.14 31.89 ⁄ L ⁄ L
Polycyclic aromatic hydrocarbons
Benz[a]anthracene (ng/cig.) 13.84 19.76 14.55 17.50 0.76 3.39 ⁄ L ⁄ L
Benzo[b]ﬂuoranthene (ng/cig.) 7.18 9.91 7.88 9.53 0.38 1.25 ⁄ L ⁄ L
Benzo[j]ﬂuoranthene (ng/cig.) 4.18 6.19 4.74 5.28 0.30 1.04 ⁄ L ⁄ L
Benzo[a]pyrene (ng/cig.) 8.73 12.25 9.10 10.91 0.34 1.70 ⁄ L ⁄ L
Indeno(1,2,3-cd)pyrene (ng/cig.) 3.94 5.74 4.10 5.08 0.21 0.73 ⁄ L ⁄ L
Pyrene (ng/cig.) 47.35 70.25 52.07 60.65 2.16 11.13 ⁄ L ⁄ L
Cytotoxicity
1/EC50: GVP fraction (ml/cig.) 87.37 164.7 87.00 143.2 54.1 120.3 ⁄ L ⁄ L
1/EC50: TPM fraction (ml/cig.) 147.1 202.1 153.04 177.2 72.2 114.4 ⁄ L ⁄ L
Bacterial mutagenicity (TPM fraction)
Strain TA98 with S9 (rev./cig.) 26390 34189 27945 34953 3134 14472 ⁄ L ⁄ L
Strain TA100 with S9 (rev./cig.) 12878 21107 13272 20311 837 10829 ⁄ L ⁄ L
Strain TA1537 with S9 (rev./cig.) 3687 7963 4392 6279 450 3072 ⁄ L ⁄ L
Abbreviations: CL, conﬁdence limit; GVP, gas–vapor phase; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN, N-nitrosonornicotine; and TPM, total particulate
matter.
=: Overlap of 95% conﬁdence intervals; ⁄: 95% conﬁdence interval of smoke constituent concentration/toxicological effect at a nicotine concentration of 1.08 mg/cig. either
signiﬁcantly higher (H) or signiﬁcantly lower (L) for EHCSS-K6 than for M6UK or PM1 (level of signiﬁcance a = 0.05).
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was compared to the conﬁdence intervals for M6UK and PM1 for
each HPHC and in vitro toxicity parameter. In cases in which there
was no overlap between two conﬁdence intervals, the difference
between the corresponding smoke constituent and in vitro toxicity
parameters of the two cigarettes was regarded as statistically sig-
niﬁcant (a = 0.05). At a nicotine concentration of 1.08 mg/cigarette,74% of the HPHC concentrations and toxicological effects were sta-
tistically signiﬁcantly lower for the EHCSS-K6 cigarette compared
to both, the M6UK and the PM1, suggesting a signiﬁcant potential
for reduced exposure at the ‘product level’.
Examining the ‘smoker level’, nicotine uptake distributions for
M6UK, PM1, and EHCSS-K6 cigarettes (Fig. 3) were calculated from
clinical study data (Tricker et al., 2012) as an average daily excre-
Fig. 3. Nicotine uptake distributions of M6UK, PM1, and EHCSS-K6. (a)
Fig. 4. Overlay plots of frequency distributions for selected smoke constituents (a)
formaldehyde, (b) carbon monoxide, (c) 1,3-butadiene, (d) acrolein, and (e) NNK.
S90 H.-Jörg Urban et al. / Regulatory Toxicology and Pharmacology 64 (2012) S85–S97tion on days 3–8 (N = 192, 181, and 180 values for M6UK, PM1, and
EHCSS-K6 smokers, respectively) using a correction factor of 1.25
to convert measured Neq to total nicotine excretion (Schepers
and Demetriou, 2002). Daily Neq excretion was then divided by
the reported number of cigarettes consumed to obtain the nicotine
uptake distributions.
Fig. 4 present examples of histogram plots of distributions of (a)
formaldehyde, (b) carbon monoxide, (c) 1,3-butadiene, (d) acrolein,
and (e) NNK uptake determined using the ‘nicotine bridging’ meth-
od with normal distribution ﬁts for the M6UK and PM1 cigarettes,
and log-normal distribution for the EHCSS-K6 cigarette. The
parameters needed to deﬁne the ﬁtted curves (mean/mode and
standard deviation) as well as the 10th and 90th percentile for
all HPHC/in vitro toxicity parameters are summarized in Table 3.
Percentage changes and the overlap corresponding to the com-
parison EHCSS-K6 vs. M6UK and EHCSS-K6 vs. PM1 are estimated
for HPHC/in vitro toxicity parameters and summarized in Table 4.
For the 39 comparisons presented in Table 4, the means/modes
of the HPHC and in vitro toxicity parameters showed a percentagechange ofP90% for 20 (51%) and 18 (46%) of EHCSS-K6 vs. M6UK,
and EHCSS-K6 vs. PM1 comparisons, respectively. According to the
inverse relationship, a similar pattern was observed for the over-
lap: smoke constituent and in vitro toxicity parameters displayed
an overlap of 610% for 28 (71%) and 24 (61%) of EHCSS-K6 vs.
M6UK, and EHCSS-K6 vs. PM1 comparisons, respectively. Water
and ammonia were higher in EHCSS-K6, compared to M6UK and
PM1. TPM and formaldehyde were higher in EHCSS-K6, compared
to PM1. For all other HPHC and in vitro toxicity parameters, EHCSS-
K6 had a lower mode than the mean of the two CC.
Examining the proportions of the distributions between the
‘lower tail’ (610%) of CC vs. the ‘upper tail’ (P90%) of EHCSS-K6,
the 10th percentile of M6UK uptake was above the 90th percentile
of EHCSS-K6 uptake for 28 of 39 parameters (72%) (Table 3). In 26
out of 39 parameters (67%), the 10th percentile of the PM1 uptake
was above the 90th percentile of the EHCSS-K6 (Table 3). In con-
trast, for only one of the 39 parameters determined in CC, the
10th percentile of the M6UK uptake was above the 90th percentile
of PM1.
Biomarkers of exposure to eight selected HPHC including nico-
tine (Tricker et al., 2012) were determined in urine samples and
the percentage change estimates based on mean changes from
days 3–8 compared to those obtained using the ‘nicotine bridging’
method (Table 5). As an index of similarity, the ratio between bio-
marker of exposure measurements and ‘nicotine bridging’ esti-
mates are also presented; a ratio equal to 1.0 indicates similarity.
The differences between the two methods are 68% for EHCSS-
K6 vs. M6UK (except for 1,3-butadiene and NNK) and 613% for
EHCSS-K6 vs. PM1 (except for 1,3-butadiene, acrolein, and NNK)
supporting the validity of the ‘nicotine bridging’ method. For 1,3-
butadiene and NNK larger differences between the two methods
were observed (14% for 1,3-butadiene and 16% for NNK in the
EHCSS-K6 vs. M6UK comparisons; 32% for 1,3-butadiene and 20%
for NNK for the EHCSS-K6 vs. PM1 comparisons). One outlier is
the difference of 69% for acrolein in the comparison EHCSS-K6 vs.
PM1 which cannot be explained based on the available data.
Reduced exposure assessment can be extended to the ‘popula-
tion level’ by comparing nicotine uptake distributions of the ciga-
rettes smoked in the clinical study ‘test population’ (PM1 and
M6UK) (Tricker et al., 2012) to nicotine uptake distributions of cig-
Fig. 4. (continued)
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tion’ (Lindner et al., 2011). As presented in Fig. 5, median nicotine
uptake was 0.86, 1.01, and 1.16 mg nicotine/cigarette for the TC1,
TC2, and TC3 ISO tar yield cigarette categories, respectively.
A criterion for similarity (test population/reference population)
used was the 90% conﬁdence interval of the median nicotine
uptake (ratio of medians of test/reference), which should lie within
the interval of 0.8–1.25. As shown in Fig. 3, median nicotine uptake
in the ‘test population’ was 0.62 and 0.99 mg nicotine/cigarette for
PM1 and M6UK cigarettes, respectively. In the ‘reference popula-tion’ the ratio of median nicotine uptake (90% conﬁdence intervals)
were 0.722 (90% CI: 0.695–0.780) and 0.977 (90% CI: 0.929–1.088)
mg nicotine/cigarette for tar categories TC1 and TC2, respectively,
suggesting that the criteria were met for the latter comparison.
The apparent low median nicotine uptake of the ‘test population’
smoking PM1 (1 mg ISO tar) cigarettes weighs disproportionally
against the higher variability and median nicotine uptake in the
1–4 mg ISO tar yield range ‘reference population’ (ratio 0.722
(90% CI: 0.695–0.780), thus, falling just short of meeting the crite-
rion for similarity in this example.
Table 3
Nicotine bridging for 34 smoke constituents and 5 toxicity parameters.
Cigarette smoke constituent/toxicity
parameter
Unit M6UK PM1 EHCSS-K6
(mean ± SD) 10th
Percentiles
90th
Percentiles
(mean ± SD) 10th
Percentiles
90th
Percentiles
(mean ± SD) 10th
percentiles
90th
percentiles
Mode
TPM (mg/cig.) 16.6 ± 5.41 10.0 23.5 9.2 ± 3.12 6.2 13.8 15.5 ± 4.72 10.5 23.9 13.8
Tar (mg/cig.) 12.9 ± 3.82 8.3 17.8 7.6 ± 2.59 5.2 11.5 8.2 ± 2.53 5.4 12.7 7.2
Nicotine (mg/cig.) 1.0 ± 0.26 0.7 1.3 0.7 ± 0.22 0.5 1.0 0.6 ± 0.25 0.4 1.1 0.5
Water (mg/cig.) 2.7 ± 1.33 1.1 4.4 0.8 ± 0.30 0.6 1.3 6.7 ± 1.94 4.7 10.2 6.1
Carbon monoxide (mg/cig.) 15.8 ± 4.38 10.5 21.4 9.5 ± 2.64 7.0 13.5 1.2 ± 1.00 0.5 2.8 0.7
Aliphatic dienes
1,3-Butadiene (lg/cig.) 40.8 ± 11.02 27.4 54.9 28.4 ± 8.35 20.4 40.8 4.4 ± 2.83 2.3 9.1 3.0
Isoprene (lg/cig.) 481.1 ± 145.1 304.3 667.2 409.1 ± 132.2 283.8 606.2 66.5 ± 22.12 42.8 105.9 57.9
Aldehydes
Formaldehyde (lg/cig.) 36.7 ± 13.49 20.3 54.0 10.8 ± 3.69 7.3 16.3 35.3 ± 10.19 24.4 53.4 31.8
Acetaldehyde (lg/cig.) 712.7 ±215.5 450.2 988.9 509.5 ± 182.4 336.6 781.4 259.8 ± 67.37 187.7 379.9 238.7
Acrolein (lg/cig.) 80.2 ± 24.15 50.8 111.1 46.5 ± 16.60 30.8 71.3 43.8 ± 12.75 30.1 66.5 39.4
Propionaldehyde (lg/cig.) 60.2 ± 17.38 39.0 82.5 42.5 ± 15.05 28.2 64.9 11.9 ± 3.48 8.1 18.1 10.7
Acid derivates
Acetamide (lg/cig.) 9.0 ±3.23 5.1 13.2 4.1 ± 1.58 2.6 6.4 3.2 ± 1.43 1.7 5.8 2.5
Acrylonitrile (lg/cig.) 25.5 ± 9.87 13.4 38.1 21.0 ± 7.52 13.9 32.2 1.8 ± 1.42 0.8 4.1 1.1
Nitro compounds
2-Nitropropane (ng/cig.) 11.1 ± 3.11 7.3 15.1 9.4 ± 3.49 6.1 14.7 9.6±3.15 6.2 15.2 8.4
Aromatic amines
o-Toluidine (ng/cig.) 68.1 ± 16.72 47.7 89.5 48.5 ± 16.09 33.2 72.5 5.0 ± 7.41 1.0 15.0 1.2
o-Anisidine (ng/cig.) 2.7 ± 0.62 2.0 3.5 2.2 ± 0.68 1.5 3.2 0.4 ± 0.17 0.2 0.7 0.3
2-Naphthylamine (ng/cig.) 7.7 ± 1.34 6.0 9.4 6.0 ± 1.68 4.4 8.5 0.5 ± 0.61 0.1 1.3 0.1
4-aminobiphenyl (ng/cig.) 1.6 ± 0.42 1.1 2.2 1.2 ± 0.33 0.9 1.7 0.2 ± 0.09 0.1 0.3 0.1
Inorganic compounds
Nitrogen oxides (lg/cig.) 167.4 ± 38.47 120.5 216.7 127.8 ± 22.19 106.7 160.8 60.0 ± 19.54 39.1 94.8 52.6
Ammonia (lg/cig.) 12.9 ± 3.87 8.2 17.8 8.5 ± 0.86 7.7 9.7 23.4 ± 6.74 16.2 35.4 21.1
Hydrogen cyanide (lg/cig.) 105.8 ± 43.76 52.5 161.9 69.8 ± 28.95 42.4 113.0 16.9 ± 8.35 7.9 31.7 12.2
Monocyclic aromatic hydrocarbons
Benzene (lg/cig.) 49.1 ± 12.58 33.8 65.2 37.2 ± 11.86 26.0 54.9 1.3 ± 1.20 0.5 3.2 0.7
Toluene (lg/cig.) 81.2 ± 24.31 51.6 112.4 67.1 ± 23.00 45.3 101.4 3.3 ± 2.20 1.7 7.0 2.3
Styrene (lg/cig.) 8.8 ± 4.16 3.7 14.1 7.3 ± 2.97 4.4 11.7 0.6 ± 0.41 0.3 1.2 0.3
N-nitrosamines
NNN (lg/cig.) 74.2 ± 12.85 58.5 90.6 56.1 ± 7.23 49.2 66.8 46.6 ± 18.50 26.8 79.6 38.2
NNK (lg/cig.) 51.6 ± 8.99 40.7 63.1 39.7 ± 9.38 30.8 53.6 13.4 ± 5.67 7.3 23.5 10.7
Phenols
Phenol (lg/cig.) 15.2 ± 4.03 10.3 20.3 12.4 ± 4.66 7.9 19.3 2.6 ± 4.95 0.3 8.3 0.3
Catechol (lg/cig.) 59.7 ± 12.59 44.4 75.8 42.6 ± 12.97 30.3 62.0 14.7 ± 7.14 7.1 27.5 10.9
Polycyclic aromatic hydrocarbons
Benz[a]anthracene (ng/cig.) 15.6 ± 3.91 10.9 20.6 10.3 ± 3.36 7.2 15.3 0.5 ± 0.94 0.1 1.6 0.1
Benzo[b]ﬂuoranthene (ng/cig.) 8.0 ± 1.95 5.6 10.5 5.6 ± 1.83 3.9 8.3 0.2 ± 0.34 0.0 0.7 0.0
Benzo[j]ﬂuoranthene (ng/cig.) 4.8 ± 1.25 3.3 6.4 3.4 ± 0.93 2.5 4.8 0.2 ± 0.34 0.0 0.6 0.0
Benzo[a]pyrene (ng/cig.) 9.8 ± 2.30 7.0 12.7 6.5 ± 2.09 4.5 9.6 0.3 ± 0.39 0.0 0.8 0.0
Indeno(1,2,3-cd)pyrene (ng/cig.) 4.5 ± 1.12 3.1 5.9 3.0 ± 0.96 2.1 4.4 0.1 ± 0.18 0.0 0.4 0.0
Pyrene (ng/cig.) 54.7 ± 13.57 38.1 72.1 36.4 ± 11.82 25.1 54.0 1.6 ± 2.39 0.3 4.9 0.4
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Reducing toxicants levels in cigarette smoke, normalized per
milligram of nicotine, has been advocated by the World Health
Organization (WHO) as a public health goal (Burns, 2006; Burns
et al., 2008; World Health Organization Study Group on Tobacco
Product Regulation, 2008). According to Hammond et al. (2007),
‘‘[t]he use of toxin: nicotine ratios appears to be gaining momen-
tum as a potential regulatory strategy.’’ Therefore, we used this
concept to model HPHC exposure reduction for the EHCSS series-
K cigarette using a testing strategy incorporating chemical analysis
of cigarette smoke (Zenzen et al., 2012) and clinical study data in
which excretion of nicotine uptake was determined (Tricker
et al., 2012) to predict exposure reduction to selected HPHC for
which biomarkers of exposure are not available (Schorp et al.,
2012).
The measurement of biomarkers of exposure in biological ﬂu-
ids has become an accepted method to conduct assessments of
tobacco smoke exposure (Institute of Medicine 2001, 2012;
Hatsukami et al., 2007; World Health Organization Study Group
on Tobacco Product Regulation, 2007; Food and Drug Administra-
tion, 2012). Nicotine and its metabolites meet most of the desired
criteria for a biomarker of exposure to tobacco and tobacco
smoke (Tricker, 2006). However, no suitable biomarkers of expo-
sure exist for the majority of the approximately 5300 compounds
identiﬁed in cigarette smoke (Rodgman and Perfetti, 2009). In
most cases for which a biomarker of exposure exists, the pharma-
cokinetics are not understood adequately to justify that a mea-
sured biomarker will reliably measure the uptake of the parent
smoke component. In the few cases in which a speciﬁc biomarker
exists, such as nicotine-derived biomarkers of exposure, two inde-
pendent measures (i.e., HPHC quantiﬁcation via smoking ma-
chines and biomarkers of exposure measurements from body
ﬂuids) can be linked using a method, which we term ‘nicotine
bridging’ (Fig. 1).
The ‘nicotine bridging’ method depends on the assumption that
all cigarette smoke constituents are retained to the same extent as
nicotine. However, several experimental studies investigating the
retention of individual smoke constituents (Dalhamn et al., 1968;
Gori et al., 1986; Armitage et al., 2004a,b; Baker and Dixon,
2006; Moldoveanu and St. Charles, 2006; Feng et al., 2007; Mold-
oveanu et al., 2007, 2008a,b,c) suggest that this default assumption
represents a worst-case situation, since the extent of nicotine up-
take (90–100%) exceeds that of many other HPHC. This is assumed
to be valid for all types of smoking behavior (e.g., different puff
proﬁles and inhalation patterns).
The ‘nicotine bridging’ method requires smoke chemistry data
from cigarettes smoked according to multiple regimens (Zenzen
et al., 2012) to construct HPHC-to-nicotine uptake distributions.
As such, the ‘nicotine bridging’ method addresses the limitation
of the ‘‘one machine-smoking protocol – one yield’’ (i.e., point esti-
mate) approach and incorporates population-based variability
from nicotine exposure frequency distributions (Figs. 1 and 5),
and requires that the same cigarette is machine-smoked under
multiple combinations and settings for puff volumes, puff dura-
tions, inter-puff intervals; an approach that we term machine
smoking under ‘human pufﬁng behavior’ conditions.
Exposure to smoke constituents other than nicotine for which
biomarkers of exposure cannot be directly assessed are estimated
by establishing a statistical relationship between both HPHC and
nicotine. Since biomarkers of exposure to nicotine can be directly
measured in clinical studies and nicotine uptake distributions cal-
culated (Fig. 1), exposure distributions for other HPHC can be esti-
mated. Consequently, differences in exposure to HPHC from
different cigarette designs, e.g., in smokers of CC and smokers
Table 4
Percentage change (%) and overlap (%) characteristics for 34 smoke constituents and 5 toxicity parameters.
Cigarette smoke constituent/toxicity parameter EHCSS-K6 vs. M6UK comparison EHCSS-K6 vs. PM1 comparison
% Change % Overlap L % Change % Overlap L
TPM (mg/cig) 16.7 84.9 17.2 50.5 39.9 11.9
Tar (mg/cig) 44.0 41.3 10.4 5.6 98.9 9.4
Nicotine (mg/cig) 48.3 42.2 0.8 26.3 80.3 0.6
Water (mg/cig) 126.7 16.6 4.5 617.0 0.0 2.2
Carbon monoxide (mg/cig) 95.6 1.0 4.8 92.6 2.6 3.7
Aliphatic dienes
1,3-butadiene (lg/cig) 92.7 1.1 13.8 89.4 3.3 11.3
Isoprene (lg/cig) 88.0 1.3 146.7 85.8 2.5 137.7
Aldehydes
Formaldehyde (lg/cig) 13.5 86.4 41.3 194.3 2.6 19.3
Acetaldehyde (lg/cig) 66.5 10.0 399.9 53.2 27.4 358.9
Acrolein (lg/cig) 50.9 29.4 59.2 15.4 84.6 50.8
Propionaldehyde (lg/cig) 82.3 2.1 22.9 74.9 8.6 20.0
Acid derivates
Acetamide (lg/cig) 72.3 20.1 5.3 38.5 70.0 3.6
Acrylonitrile (lg/cig) 95.7 3.1 6.0 94.8 3.0 5.8
Nitro compounds
2-Nitropropane (ng/cig) 24.6 74.6 10.2 11.4 94.1 10.8
Aromatic amines
o-Toluidine (ng/cig) 98.3 1.5 26.0 97.6 5.3 17.3
o-Anisidine (ng/cig) 90.5 0.8 1.1 88.2 4.2 0.9
2-Naphthylamine (ng/cig) 98.1 0.3 3.4 97.6 2.0 2.1
4-Aminobiphenyl (ng/cig) 94.5 1.1 0.6 92.3 3.2 0.5
Inorganic compounds
Nitrogen oxides (lg/cig) 68.6 7.0 100.4 58.8 10.9 90.8
Ammonia (lg/cig) 63.4 28.3 17.3 148.7 0.5 11.1
Hydrogen cyanide (lg/cig) 88.4 8.4 38.9 82.5 14.8 33.2
Monocyclic aromatic hydrocarbons
Benzene (lg/cig) 98.7 0.1 9.1 98.2 0.7 6.7
Toluene (lg/cig) 97.2 0.4 14.0 96.6 1.0 12.1
Styrene (lg/cig) 96.1 5.3 1.7 95.3 3.9 1.7
N-nitrosamines
NNN (lg/cig) 48.5 32.0 57.9 31.9 52.2 46.5
NNK (lg/cig) 79.3 2.0 30.1 73.1 9.2 23.9
Phenols
Phenol (lg/cig) 98.4 7.2 7.0 98.0 14.5 5.1
Catechol (lg/cig) 81.8 3.9 33.2 74.5 16.8 25.3
Polycyclic aromatic hydrocarbons
Benz[a]anthracene (ng/cig) 99.7 0.6 4.6 99.5 2.4 2.8
Benzo[b]ﬂuoranthene (ng/cig) 99.4 0.3 2.1 99.1 1.6 1.3
Benzo[j]ﬂuoranthene (ng/cig) 99.7 0.9 1.4 99.6 1.6 1.1
Benzo[a]pyrene (ng/cig) 99.5 0.2 2.7 99.3 1.6 1.5
Indeno(1,2,3-cd)pyrene (ng/cig) 99.1 0.3 1.1 98.7 1.6 0.7
Pyrene (ng/cig) 99.3 0.3 14.6 98.9 1.8 9.1
Cytotoxicity
1/EC50: GVP fraction (per cig) 68.7 22.7 69.9 48.3 52.6 56.3
1/EC50: TPM fraction (per cig) 85.4 8.9 85.2 77.4 25.4 62.9
Bacterial mutagenicity (TPM fraction)
Strain TA98 with S9 (rev./cig) 97.8 1.8 14895 96.9 5.7 8457
Strain TA100 with S9 (rev./cig) 97.5 0.8 8397 96.2 4.7 3850
Strain TA1537 with S9 (rev./cig) 97.5 1.5 1870 96.2 5.1 1372
Abbreviations: GVP, gas–vapor phase; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN, N-nitrosonornicotine; and TPM, total particulate matter.Change (%) and
overlap (%) for the comparison of means for each smoke constituent and toxicity parameter (EHCSS-K6 vs. M6UK and EHCSS-K6 vs. PM1) as well as the interval length (L)
corresponding to equal frequency which was used to estimate the overlap.
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analysis of smoke chemistry data and measured nicotine uptake,
contributing to the discussion related to what constitutes ‘substan-
tial exposure reduction’ (FDA, 2011), i.e., demonstrating the extent
of separation of the exposure distribution curves.
Additionally, we investigated the use of nicotine uptake distri-
butions for CC as a measure of similarity between two populations;
nicotine uptake determined in a conﬁned clinical study ‘test’ pop-
ulation (Tricker et al., 2012) and nicotine uptake determined in a
‘reference’ population (Lindner et al., 2011). The clinical data usedin the current study were obtained from subjects smoking only
M6UK, PM1 and EHCSS-K6 cigarettes. Several population-based
exposure studies demonstrate that variations in nicotine uptake
between individuals as well as within groups of smokers exist
due to complex patterns of individual smoking behavior. Therefore,
it is not surprising that nicotine biomonitoring results in a wide
distribution of nicotine uptake per cigarette ISO nicotine yield
(e.g., Ueda et al., 2002; Scherer et al., 2007; Mendes et al., 2009).
Thus, we compared the nicotine uptake distributions for M6UK
and PM1 cigarettes in a clinical study (Tricker et al., 2012) to data
Table 5
Method comparisons: Percentage change in biomarkers of exposure and estimates based on nicotine bridging.
Cigarette smoke
constituent
Change EHCSS-K6 vs. M6UK (%) Change EHCSS-K6 vs. PM1 (%)
Biomarker of
exposure
Nicotine
bridging
Ratio (biomarker/
bridging)
Biomarker of
exposure
Nicotine
bridging
Ratio (biomarker/
bridging)
Nicotine 36.3 36.9 0.98 10.7 10.1 1.06
Carbon monoxide 85.8 92.3 0.93 81.1 87.2 0.93
1,3-Butadiene 76.8 89.3 0.86 57.2 84.7 0.68
Acrolein 41.7 45.4 0.92 9.9 5.9 1.69
o-Toluidine 99.7 92.7 1.07 99.4 89.7 1.11
Benzene 90.6 974 0.93 84.0 96.5 0.87
NNK 86.1 74.0 1.16 79.5 66.2 1.20
Pyrene 100.0 97.0 1.03 100.0 95.5 1.05
Mean 0.99 1.07
Standard deviation 0.10 0.30
Abbreviation: NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Fig. 5. Nicotine uptake frequency distributions for smokers of different ISO tar yield cigarettes.
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2011), concluding that similarity essentially exists.
4.1. Reduced exposure substantiation heuristic
The presented ‘nicotine bridging’ approach closes the loop on
assessing exposure reduction (Schorp et al., 2012). Overall, ademonstration of reduced exposure across the product level
(‘yield’ as determined under standard smoking regimen and ‘hu-
man pufﬁng behavior’), the smoker level (clinical studies to
determine nicotine uptake and other biomarkers of exposure),
and the population level (test of equivalence between test and
reference populations) provides factual evidence of exposure
reduction.
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product performed as follows:
(1) 74% of HPHC and toxicity parameters were statistically sig-
niﬁcantly lower (p = 0.05, 95% CI) in the EHCSS-K6 vs. CC
at the 90th percentile of the nicotine uptake distribution of
the EHCSS-K6 (1.08 mg/cigarette). In other words, at approx-
imately the 1 mg/cigarette median nicotine uptake found in
many population-based biomonitoring studies, the test
product exhibits a signiﬁcant potential for exposure
reduction.
(2) For HPHC uptake proportional to nicotine uptake distribu-
tion, 50% of the ‘percent reductions’ are P90% and ‘overlap’
is 610% of EHCSS-K6 vs. CC.
(3) For HPHC uptake proportional to nicotine uptake distribu-
tion: 50% of the ‘lower tail’ (610%) of the CC distribution is
below the ‘upper tail’ (P90%) of the EHCSS-K6 distribution,
and
(4) Similarity, as assessed by median nicotine uptake ratios for
the two separate ‘‘tar category’’ (TC) smoker populations
(90% conﬁdence interval of ratio of medians of test/reference
population is within the range of 0.8–1.25) was 0.722 (90%
CI: 0.695–0.780) and 0.977 (90% CI: 0.929–1.088) for TC 1
and TC 2, respectively.
These examples highlight both the signiﬁcant product-speciﬁc
reduced exposure potential of the EHCSS-K6 vs. CC. already
achieved, and the quest for continuous improvement of this plat-
form benchmarked against the data presented here.5. Conclusion
This study introduces the concept of ‘nicotine bridging’ to esti-
mate the distribution of HPHC uptake in a population of smokers
based on relationships between analytical smoke chemistry data
and the distribution of nicotine uptake in smokers. Because the
method is nicotine-based, and nicotine is the most studied and
well understood smoke constituent with established pharmacoki-
netics and biomarker methodologies, the use of nicotine uptake
distributions from smoker populations provides a scientiﬁcally
sound basis for further analyses. Under the conservative assump-
tion that other smoke constituents are retained to the same extent
(or lower) than nicotine, modeling of HPHC uptake proportional to
nicotine provides an experimental concept that we call ‘nicotine
bridging’ for estimating exposure and uptake of HPHC for which
no biomarkers of exposure are available. Although ‘nicotine bridg-
ing’ is still an experimental concept that requires further valida-
tion, we intend to use this heuristic to evaluate exposure
reduction as a necessary, but not sufﬁcient component to justify
the potential for risk reduction.Conﬂict of interest statement
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